On January 14, 2026 Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, reported they have entered into a strategic-development agreement under which Fresenius Kabi has an exclusive license to develop, manufacture, and distribute products that incorporate TQ Therapeutics’ proprietary cell selection technology. The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Fresenius Kabi is a leading provider of essential medicines and medical technologies. TQ Therapeutics specializes in proprietary cell selection technology and following therapeutic applications. Under the agreement, TQ Therapeutics’ affinity and column-based cell isolation technology will be integrated into Fresenius Kabi’s Cue Cell Processing System. By combining these technologies, the companies aim to create an automated and robust system that can isolate T cells from whole blood and apheresis products in less than two hours for cell and gene therapy manufacturing applications. The goal is to quickly, easily and consistently produce high purity T cells, helping therapeutic developers work more efficiently and potentially bring treatments to patients faster.
"With this collaboration, we are reinforcing our commitment to innovation in cell and gene therapy technology," said Saurabh Bhasin, Head of Portfolio, Cell Therapies & Contract Manufacturing Operations at Fresenius Kabi. "By integrating TQ Therapeutics’ novel selection technology into our Cue system, our aim is to improve manufacturing success and scalability—key steps toward supporting the advancement of cell and gene therapies."
TQ Therapeutics’ goal is to leverage the Cue system and its integrated cell selection column technology to develop extracorporeal, ultra-short cell and gene therapy processes for clinical applications creating faster steps that can be performed closer to the point of care to help simplify and accelerate treatment workflows.
"This agreement with Fresenius Kabi allows us to bring our proprietary technology to a broader audience with the goal of accelerating the development of next-generation cell therapies," said Christian Eckert, chief executive officer of TQ Therapeutics. "With Fresenius Kabi’s expertise in cell and gene therapy device technologies development and commercialization, and TQ Therapeutics’ focus on developing ultra-short processes for clinical cell therapies from manufacturing to in vivo applications, we are creating a novel value proposition for scaling and enabling the supply of cell therapies for broader patient populations."
Cell and gene therapy is an emerging segment of medicine that has shown promise in treating certain cancers and other conditions.
Phacilitate Advanced Therapies Week 2026
Fresenius Kabi and TQ Therapeutics will debut the Cue Cell Processing System and the in-development cell selection module at Booth #623 on February 10-12 during Phacilitate ATW 2026 in San Diego, CA. Attendees are invited to visit the booth to learn more about the technology and its development.
(Press release, Fresenius, JAN 14, 2026, View Source [SID1234662052])